At a glance
ClinicalIndex Comparison Record- ✓Adult male, age 20–60 years
- ✓Overweight and obese with BMI 27.5 < BMI ≤ 34.9
- ✓Significant abdominal subcutaneous fat (waist-to-hip ratio ≥ 0.9)
- ✓Weight stable over last 3 months
- ✕Weight change >5% of current body weight in last 3 months
- ✕Unable to tolerate subcutaneous injection
- ✕Uncontrolled cardiac, hepatic, renal, or neurologic/psychiatric disorders
- ✕Positive for HBV, HCV, or HIV
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Blind, Randomized, Placebo Controlled, Dose Escalation Phase 2a Clinical Trial for the Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers
In Brief
A Phase 2 clinical trial evaluating RZL-012 and Placebo for Obesity and 2 related conditions. Completed, enrolled 32 participants across 1 site.
Detailed Summary
Obesity is a direct result of food-intake in excess of body energy expenditure. Thus, induction of increased energy expenditure via the activation of thermogenesis at targeted anatomical sites can counterbalance obesity. This trial aims to study RZL-012, a novel compound, in treating obesity by activating thermogenesis in subcutaneous fat.
Study Details
Timeline
Interventions
Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.